Novartis reveals positive data from Phase III ORION trials of inclisiran

By Akshay Kedari  Date: 2020-08-31

Novartis reveals positive data from Phase III ORION trials of inclisiran

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inclisiran. For the record, inclisiran is a first-in-class investigational hyperlipidemia treatment for adults.

According to reliable sources, this latest analysis of inclisiran revealed a highly reliable effect, with tolerability and safety profile parallel to placebo, with two dosing schedules every year across individual patients suffering from atherosclerotic cardiovascular disease (ASCVD) or equivalent risks lasting more than 17 months of medication.

Reportedly, these results were presented in the annual meeting of the European Society of Cardiology at the ESC Congress 2020. The analysis tested the tolerability and efficacy of inclisiran in over 2,300 patients.

Speaking on the move, Kausik Ray, M.D., the principal investigator of ORION-11 and Consultant Cardiologist, Professor of Public Health at Imperial College London, said that this trial establishes that as a small interfering RNA, inclisiran offers an oddly consistent treatment model. Almost all patients from these studies attained clinically meaningful drops in LDL-C levels over the span of 17 months.

Meanwhile, inclisiran posted a tolerability and safety profile coherent to placebo. As a result, these safety and efficacy results establish the promise of inclisiran as a prominent medication for ASCVD patients that failed to accomplish their LDL-C goals, continued Kaausik.

As for David Soergel, M.D., Global Head of Drug Development, CVM at Novartis, there is a crucial need for novel LDL-C-lowering treatments for patients that are not attaining their LDL-C targets with current treatment options.

The study reinforced their trust in inclisiran’s potential as the first cholesterol-lowering siRNA and its therapeutic value. Taking the new twice-yearly dosing approach, still subject for approval, inclisiran might help the company reimagine ASCVD treatment and bode well patient’s regular healthcare visits, added Soergel.

Source Credit: https://www.novartis.com/news/media-releases/novartis-new-analysis-shows-high-consistency-lowering-ldl-c-individual-response-investigational-inclisiran

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Tiger Global looking to raise USD 10 billion to create new venture fund

Tiger Global looking to raise USD 10 billion to create new venture fund

By Akshay Kedari

American investment firm Tiger Global is reportedly looking to create a capital fund for startups by securing USD 10 billion from investors. So far, the company has participated in over 100 investment rounds since the past three months and has manage...

Urban Company secures USD 190 million in funding round led by Prosus

Urban Company secures USD 190 million in funding round led by Prosus

By Akshay Kedari

Urban Company, an Indian gig marketplace that provides home maintenance services, has secured USD 190 million in a funding round which was led by Prosus N.V. Other participants in the fundraising included companies such as Steadview Capital, Tiger Gl...

Samsung might launch a foldable Android tablet in first quarter of 2022

Samsung might launch a foldable Android tablet in first quarter of 2022

By Akshay Kedari

After introducing three foldable smartphones in the past couple of years, South Korean multinational conglomerate Samsung Electronics is reportedly working on its first tri-folding Android tablet. According to reliable sources, the new product is lik...

Remote hiring startup Deel secures USD 156 million in Series C funding

Remote hiring startup Deel secures USD 156 million in Series C funding

By Akshay Kedari

Deel, a company that specializes in offering recruitment, payroll, and compliance tools, has reportedly secured USD 156 million during a Series C funding round which was led by YC Continuity Fund. The California-based startup has now reached a valuat...

Audi unveils the A6 e-Tron concept with 700 km range and 800 Nm torque

Audi unveils the A6 e-Tron concept with 700 km range and 800 Nm torque

By Akshay Kedari

Audi AG, a German multinational auto manufacturer of luxury vehicles has unveiled the A6 e-Tron concept which is soon likely to be made available globally. The production version which is expected to have a range of 700 km (more than 400 miles) is to...